

Express Mail No.: EV 869858665 US
Date of Deposit: August 22, 2006

Page 1 of 1
Attorney Docket No.: 22058-514 NATL

Please type a plus sign (+) in this box



Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/868,123
	Filing Date	April 2, 2002
	First Named Inventor	Collins
	Group Art Unit	1647
	Examiner Name	Regina M. DeBerry
	Attorney Docket Number	22058-514 NATL

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication mm/dd/yyyy	Translation Yes No		
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
RM	C20	Bost et al. <i>Immunology</i> , 87:633-641 (1996)					
	C21	Grünig et al. <i>Science</i> , 282:2261-2263 (1998)					
RM	C22	Van Der Pouw Kraan et al. <i>Clin. Exp. Immunol.</i> , 111:129-135 (1998)					

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	10/31/06
-------------------------------	--	----------------------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Express Mail Label No.: EV074978669US
Date of Deposit: May 9, 2002

COPY

Page 1 of 2

Please type a plus sign (+) in this box

+

PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/868,123
	Filing Date of U.S. Natl Appl.	06/13/01
	First Named Inventor	Collins
	Group Art Unit	Not Yet Assigned 1647
	Examiner Name	Not Yet Assigned RM DeBerry
	Attorney Docket Number	22058-514 NATL

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date if Appropriate
RO	A1	5,696,234	12/09/97	Zurawski et al.			
RO	A2	5,599,905	02/04/97	Mosley et al.			
RO	A3	5,710,023	01/20/98	Collins et al.			


FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
RO	B1	WO	97/15663	Amrad Operations Pty. Ltd.	05/01/1997		
RO	B2	WO	94/04680	Schering Corporation	03/03/1994		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
RO	C1	Obiri et al. (1995). "Receptor for Interleukin 13" <i>J. Biol. Chem.</i> 270(15): 8797-8804.					
RO	C2	Vita et al. (1995). "Characterization and Comparison of the Interleukin 13 Receptor with the Interleukin 4 Receptor on Several Cell Types" <i>J. Biol. Chem.</i> 270(8): 3512-3517.					
RO	C3	Zurawski et al. (1995). "The Primary Binding subunit of the Human Interleukin-4 Receptor Is Also a Component of the Interleukin-13 Receptor" <i>J. Biol. Chem.</i> 270(23): 13869-13878.					
RO	C4	International Search Report for PCT/US99/29493. Mailed on April 25, 2000. CONSIDER DO NOT REPLY					
RO	C5	Written Opinion for PCT/US99/29493. Mailed on January 26, 2001. CONSIDER DO NOT REPLY					
RO	C6	McKenzie et al. (1993). "Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function" <i>Proc. Natl. Acad. Sci. USA</i> 90: 3735-3739					
RO	C7	Minty et al. (1993). "Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses" <i>Nature</i> 362: 248-250					
RO	C8	Punnonen et al. (1994). "IL-13 Induces Proliferation, Ig Isotype Switching, and Ig Synthesis by Immature Human Fetal B Cells" <i>J. Immunol.</i> 152: 1094-1102					
RO	C9	Punnonen et al. (1993). "Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells" <i>Proc. Natl. Acad. Sci. USA</i> 90: 3730-3734					
RO	C10	Cocks et al. (1993). "IL-13 Induces Proliferation and Differentiation of Human B Cells Activated by the CD40 Ligand" <i>Int. Immunol.</i> 5(6): 657-663.					
RO	C11	Zurawski et al. (1993). "Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction" <i>EMBO J.</i> 12: 2663-2670					
RO	C12	Hilton et al. (1996). "Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor" <i>Proc. Natl. Acad. Sci. USA</i> 93: 497-501.					
RO	C13	Shanafelt et al. (1998). "An immune cell-selective interleukin 4 agonist" <i>Proc. Natl. Acad. Sci. USA</i> 95: 9454-9458.					

Requis M. DeBerry 10/31/06

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
	C14	Aversa et al. (1993). "An Interleukin 4 Mutant Protein Inhibits both IL-4 or IL-13 induced Human Immunoglobulin G4 and IgE Synthesis and B Cell Proliferation: Support for a Common Component Shared by IL-4 and IL-13 Receptors" <i>J. Exp. Med.</i> 178: 2213-2218.
	C15	Grunewald et al. (1998). "An Antagonistic IL-4 Mutant Prevents Type I Allergy in the Mouse: Inhibition of the IL-4/IL-13 Receptor system Completely Abrogates Humoral Immune Response to Allergen and Development of Allergic Symptoms In Vivo" <i>J. Immunol.</i> 160: 4004-4009.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	10/31/06
-----------------------	-----------------------------------------------------------------------------------	--------------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.



Express Mail No.: EV 869858342 US
Date of Deposit: October 24, 2006

Page 1 of 1
Attorney Docket No.: 22058-514 NATL

Please type a plus sign (+) in this box



PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/868,123
	Filing Date	April 2, 2002
	First Named Inventor	Collins
	Group Art Unit	1647
	Examiner Name	Regina M. DeBerry
	Attorney Docket Number	22058-514 NATL

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
AK	023	Punnonen et al., "The relative contribution of IL-4 and IL-13 to human IgE synthesis induced by activated CD4 ⁺ or CD8 ⁺ T cells", J. Allergy Clin. Immunol., 100:792-801 (1997)

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	11/1/06
---------------------------	--	------------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY

Please type a plus sign (+) in this box

+

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/868,123
	Filing Date	04/02/02
	First Named Inventor	Collins
	Group Art Unit	1647
	Examiner Name	Not Yet Assigned RM DeBery
	Attorney Docket Number	22058-514 NATL

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication mm/dd/yyyy	Translation Yes No	
RO	B3	WO	97/31946	Genetics Institute, Inc.	09/04/97		
	B4	WO	97/33913	Zymogenetics, Inc.	09/18/97		
	B5	WO	97/47741	Smithkline Beecham Corporation; and Human Genome Sciences, Inc.	12/18/97		
	B6	WO	97/47742	Smithkline Beecham Corporation; and Human Genome Sciences, Inc.	12/18/97		
	B7	WO	98/10638	Amrad Operations Pty. Ltd.	03/19/98		
	B8	EP	0 812 913	Smithkline Beecham Corporation; and Human Genome Sciences, Inc.	12/17/97		
RO	B9	FR	2 742 156	Sanofi Societe Anonyme	06/13/97		X

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
RO	C16	Caput, et al. (1996). "Cloning and Characterization of a Specific Interleukin (IL)-13 Binding Protein Structurally Related to the IL-5 Receptor α Chain" J Biol Chem 271: 16921-16926.
RO	C17	Donaldson, et al. (1998). "The Murine IL-13 Receptor α 2: Molecular Cloning, Characterization, and Comparison with Murine IL-13 Receptor α 1" J Immun 161: 2317-2324.
RO	C18	Collins, et al. (1991). "Comparison of two distinct ligand binding chains for the IL13 receptor in the mouse" J Allergy Clin Immun 99: 287. (ABSTRACT ONLY)
RM	C19	Supplementary Partial European Search Report for EP 99966166.3-2401-US9929493 dated May 13, 2002. <i>consider DO NOT PRINT</i>

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	<i>Regina M DeBery</i>	Date Considered	10/31/03
---------------------------	------------------------	------------------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.